(ANGO) AngioDynamics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ANGO) AngioDynamics, Inc. Complete Analysis Pack
AngioDynamics’ Business Model Canvas: A Quick Look
Explore AngioDynamics, Inc.’s Business Model Canvas to see how the company creates value in medical technology, serves key customer segments, and supports growth through strategic partnerships. This concise, company-specific blueprint helps you understand the moving parts behind its business model. Ready to go deeper? Get the full canvas for a complete, actionable view.
Partnerships
Distributor networks in domestic and international markets
AngioDynamics uses distributor networks to extend reach beyond direct sales, helping it serve hospitals and specialty clinics in selected U.S. and international markets. In fiscal 2025, the Company reported net sales of about $308 million, and this partner model supports access in geographies where direct coverage is thinner.
Hospitals and integrated delivery networks
Hospitals are the main buyers for AngioDynamics, Inc.’s vascular access, oncology, and endovascular products, and its fiscal 2025 net sales were about $300 million, so repeat procedure volume matters a lot. Integrated delivery networks help standardize device choices across many care sites, which can lock in recurring orders and steadier demand.
Clinical opinion leaders and specialty physicians
AngioDynamics works with interventional radiologists, cardiologists, vascular surgeons, urologists, and oncologists to drive adoption of ablation and access tools; their input shapes design, clinical data, and training. This matters in FY2025, when the company’s net sales were about $300 million, so peer-backed evidence helps convert use in real procedures.
Contract manufacturers and component suppliers
AngioDynamics, Inc. relies on contract manufacturers and component suppliers for materials, sterile inputs, and finished-device capacity, which helps keep product supply steady across a FY2025 net sales base of about $309 million. In regulated medical devices, supplier quality and continuity matter because any disruption can delay shipments, raise costs, and hurt availability.
- Suppliers support scale and product availability.
- Sterile inputs need tight quality control.
- Supply continuity protects regulated device output.
Clinical research and teaching institutions
Clinical research and teaching institutions help AngioDynamics, Inc. test devices in real care settings, train physicians, and build evidence on safety and efficacy for minimally invasive treatments. These sites also speed awareness: in FY2025, that matters because adoption in oncology and vascular care depends on peer-reviewed data and hands-on clinical education.
- Support product studies and evaluations
- Generate safety and efficacy evidence
- Train physicians on new procedures
- Expand awareness of minimally invasive options
AngioDynamics’ FY2025 Partners Power Reach, Supply, and Adoption
AngioDynamics’ key partnerships in FY2025 center on distributors, contract manufacturers, and clinical sites that keep devices available and adoption high. With net sales of about $308 million, these partners matter for supply continuity, local market access, and physician training in vascular, oncology, and endovascular care.
| Partner | FY2025 role |
|---|---|
| Distributors | Market reach |
| Contract manufacturers | Supply capacity |
| Clinical sites | Evidence, training |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for AngioDynamics covering its medical device strategy, customers, channels, revenue streams, and competitive advantages.
Customizable Excel Spreadsheet
Quickly spot AngioDynamics, Inc.’s pain points and value drivers in one concise business model snapshot.
Reference Sources
Provides a trusted source trail for AngioDynamics, Inc., helping decision-makers verify key assumptions quickly and support confident, defensible analysis.
Activities
Medical device development
AngioDynamics’ medical device development focuses on 3 core areas: vascular access, oncology, and endovascular procedures. In fiscal 2025, the work centered on engineering, prototyping, and iterative product upgrades so new systems fit physician workflows and clinical needs.
Manufacturing and sterile production
AngioDynamics manufactures sterile, single-use devices and instruments for clinical use, where precision and lot-to-lot consistency matter. Its production must meet FDA 21 CFR Part 820 and ISO 13485:2016 quality controls, because even one defect can affect patient safety and device performance.
Regulatory and quality management
AngioDynamics ties product release to clearance, compliance, and quality checks, with fiscal 2025 net sales of about $288 million underscoring how much revenue depends on FDA-ready documentation, testing, and post-market controls.
This activity matters across U.S. and international markets, where ongoing oversight helps protect approvals, limit recalls, and keep devices sellable after launch.
Direct sales and distributor management
AngioDynamics uses 2 sales routes: direct teams with specialized clinicians and distributors for wider reach. In FY2025, this model supported product evaluation, account development, and tender work across 1 network of specialty accounts, while distributor management helped extend coverage into more geographies.
- 2 sales routes: direct and distributor
- Supports clinician evaluation and tenders
- Expands geographic coverage
Clinical education and procedure support
Clinical education and procedure support help AngioDynamics, Inc. drive adoption of advanced systems by training physicians, nurses, and lab staff on device choice and procedural technique. In FY2025, that support matters because hospitals and procedure centers buy less when workflow risk is high; hands-on in-service training lowers that barrier and speeds use.
- Train physicians and staff
- Guide device selection
- Support procedural technique
- Reduce adoption friction
AngioDynamics’ FY2025 Operations Powered $288M in Sales
AngioDynamics’ key activities in FY2025 were product development, sterile manufacturing, regulatory quality control, and clinician training across vascular access, oncology, and endovascular devices. The company’s $288 million in net sales shows how much these activities depend on FDA-ready documentation, testing, and post-market oversight.
| FY2025 key activity | Data point |
|---|---|
| Net sales | $288 million |
What You See Is What You Get
Business Model Canvas
This AngioDynamics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a live section of the final file, formatted and structured the same way as the full version. Once you buy, you’ll get the complete document instantly, ready to use, edit, or present.
Resources
NanoKnife and Solero technology platforms
NanoKnife and Solero are AngioDynamics’ key oncology resources, anchoring its ablation portfolio. In FY2025, AngioDynamics reported net sales of about $314.9 million; NanoKnife supports precise soft-tissue ablation, while Solero supports microwave and radiofrequency ablation for solid tumors and benign growths.
Vascular access brand portfolio
AngioDynamics’ vascular access portfolio centers on five core brands—BioFlo, Xcela PICC, PASV, Vortex, and SmartPort—so it has a built-in base for repeat hospital use. These devices support chemotherapy, antibiotics, and dialysis access, and clinician familiarity with the brands helps sustain reorders and standardization across care teams.
Manufacturing and quality infrastructure
AngioDynamics, Inc. treats manufacturing and quality infrastructure as a core asset because its sterile catheters, ports, and intervention devices must be made under strict regulated controls. In FY2025, this base supported consistent output, traceability, and compliance, which are essential for keeping production stable and protecting device quality.
Regulatory approvals and product intellectual property
AngioDynamics, Inc.’s regulatory clearances, patents, and device know-how help defend its niche in high-barrier markets like vascular access and oncology, where FDA approvals and IP can shape who can sell. In FY2025, AngioDynamics, Inc. reported net sales of about $305 million, showing how these assets support commercialization in competitive specialty segments.
- Clearances speed market access.
- Patents protect specialty device margins.
- Know-how raises entry barriers.
Specialized sales force and distributor relationships
AngioDynamics, Inc. leans on a specialized sales force and distributor network to reach interventional and surgical users, support account access, and train clinicians. In FY2025, the Company reported about $301 million in net sales, so these field teams are a direct driver of demand generation and product adoption.
- Direct access to hospital accounts
- Clinical training for users
- Channel reach for demand generation
AngioDynamics’ Core Brands and Platforms Power $314.9M in FY2025 Sales
AngioDynamics, Inc.’s key resources are its ablation platforms, led by NanoKnife and Solero, plus its vascular access brands BioFlo, Xcela PICC, PASV, Vortex, and SmartPort. These assets helped support about $314.9 million in FY2025 net sales, with regulated manufacturing, FDA clearances, patents, and clinical know-how protecting access and margins.
| Key resource | FY2025 value |
|---|---|
| Net sales | $314.9 million |
| Core brands | 5 vascular access brands |
Value Propositions
Minimally invasive treatment options
AngioDynamics’ minimally invasive devices support oncology and vascular procedures that treat disease without major open surgery, which can shorten procedure time and widen clinical use. In FY2025, the Company reported about $307 million in net sales, showing steady demand for these lower-trauma care options.
Broad portfolio across oncology, vascular, and access care
In fiscal 2025, AngioDynamics generated about $300 million in net sales, supported by ablation, endovascular, and vascular access lines. That breadth lets hospitals buy multiple procedure tools from one supplier, which can simplify sourcing and standardize care across oncology and vascular workflows.
Precise tumor and soft tissue ablation
NanoKnife and Solero support precise tissue destruction for malignant and benign lesions, where millimeters matter near nerves and vessels. AngioDynamics reported about $305 million in FY2025 net sales, and these tools help back its move toward higher-value oncology and soft tissue ablation use cases.
Reliable vascular access for therapy delivery
AngioDynamics’ BioFlo PICCs, midline catheters, ports, and dialysis catheters are built to keep vascular access dependable for chemotherapy, IV antibiotics, and dialysis. In FY2025, AngioDynamics reported net sales of $288.6 million, with access-focused devices staying central to therapy delivery and line performance.
- Supports chemo, antibiotics, dialysis
- Focuses on reliable line performance
- Includes PICCs, ports, dialysis catheters
Specialty procedure support for clinicians
AngioDynamics’ specialty procedure support is built for interventionalists, surgeons, and critical care teams, with clinical education and workflow tools that help advanced devices fit busy care settings. In FY2025, AngioDynamics reported about $304 million in net sales, showing this support layer sits inside a real commercial platform, not just a product pitch.
- Targets high-acuity procedure teams
- Pairs devices with training and workflow help
- Supports adoption in fast-paced settings
AngioDynamics: Minimally Invasive Devices Powering Multi-Path Care
AngioDynamics’ value proposition is clear: minimally invasive oncology and vascular devices that help clinicians treat disease with less trauma and simpler workflows. In FY2025, net sales were $288.6 million, and the mix of NanoKnife, Solero, BioFlo, ports, and dialysis catheters supports multiple care paths from one supplier.
| FY2025 metric | Value |
|---|---|
| Net sales | $288.6 million |
| Core platforms | NanoKnife, Solero, BioFlo |
| Use cases | Oncology, access, dialysis |
Customer Relationships
Direct field-based account support
AngioDynamics, Inc. keeps direct, field-based ties with specialty care teams, with sales and clinical support around procedures that need fast product choice, troubleshooting, and placement help. In fiscal 2025, net sales were $305.4 million, and this hands-on model matters most in high-acuity settings where a delay can affect care.
Distributor-led customer coverage
AngioDynamics, Inc. uses distributor-led coverage to reach accounts where a direct sales team is less efficient, especially smaller or distant domestic and international sites. In FY2025, this channel helped extend market access while keeping coverage flexible across selected geographies and account sizes.
Clinical training and in-service education
Clinical training and in-service education help clinicians use AngioDynamics, Inc. devices correctly and with more confidence, especially in ablation and vascular access, where technique matters. In fiscal 2025, AngioDynamics, Inc. reported net sales of about $305 million, and hands-on education can support faster adoption, fewer use errors, and stronger repeat business.
Long-term hospital and IDN engagement
AngioDynamics builds long-term hospital and IDN ties through repeat clinical reviews, contracting, and product standardization. In fiscal 2025, this matters most in large health systems, where buying teams can keep a device in evaluation for months and then widen use across sites, supporting repeat volume and broader portfolio adoption.
Ongoing engagement drives standardization.
Product trials can expand system-wide use.
Repeat orders follow clinical trust.
Customer service and technical support
AngioDynamics, Inc. depends on fast customer service and technical support because clinicians need quick help with orders, setup, and procedure questions during patient care. That support helps keep devices in use, reduces delays, and protects continuity of care for products used in high-stakes settings.
- Fast help for orders and procedures
- Resolves issues during care
- Supports patient-facing reliability
AngioDynamics Wins Repeat Business With Clinical Support
AngioDynamics, Inc. keeps customer ties close through direct clinical support, distributor coverage, and training that helps hospitals use devices correctly. In fiscal 2025, net sales were $305.4 million, and repeat use depends on trust in high-acuity care.
| FY2025 signal | Value |
|---|---|
| Net sales | $305.4 million |
| Support model | Direct + distributor |
| Key need | Clinical training |
Channels
Direct sales to specialized clinicians and hospitals
AngioDynamics sells directly to interventional radiologists and surgeons, which fits its FY2025 revenue base of roughly $290 million. This direct channel supports technical selling, account-level relationships, and hands-on education, which matter most for complex devices used in hospitals and specialty care settings.
Distributor networks
Distributor networks extend AngioDynamics, Inc.’s reach beyond direct sales, giving the company access to domestic and international markets without adding heavy local selling cost. This channel fits geographic expansion and lower-touch accounts, where partners can move products faster and keep coverage broad.
Hospital procurement and group purchasing
Hospital procurement teams and group purchasing organizations shape AngioDynamics’ access to large health systems, because contract wins can decide pricing, product standardization, and where devices get adopted. In FY2025, AngioDynamics reported net sales of about $304 million, so even small changes in GPO coverage can move revenue meaningfully.
Clinical demonstrations and training programs
AngioDynamics, Inc. uses clinical demos and in-service training to show real workflow fit and speed adoption of new devices. In fiscal 2025, the company reported net sales of about $296 million, so these channels matter for launch and conversion in a focused, hospital-led sales model.
- Product demos reduce trial friction.
- Training builds clinician confidence.
- In-services support faster conversion.
International commercialization partners
AngioDynamics uses local commercialization partners in selected non-U.S. markets so it can reach hospitals faster while the partner handles registration, customs, field support, and service. This matters for growth outside the U.S., where market access can take months and local rules often change by country.
Key points: local partners speed entry; they reduce regulatory and logistics burden; they support customer service in-market; and they help AngioDynamics scale internationally without building full teams country by country.
- Faster market access
- Local regulatory support
- Lower logistics friction
- Better non-U.S. scale
How AngioDynamics Drives Sales Through High-Touch Hospital Channels
AngioDynamics, Inc. sells through direct reps, distributors, hospital/GPO contracts, and clinical demos, with FY2025 net sales near $296 million. These channels fit a high-touch device model, where clinician training and account coverage drive conversion in hospitals and specialty centers.
| Channel | Role | FY2025 signal |
|---|---|---|
| Direct sales | Key accounts, technical selling | ~$296M net sales |
| Distributors | Broader reach, lower cost | Used in U.S. and abroad |
| GPOs | Contract access | Influences adoption |
Customer Segments
Interventional radiologists
Interventional radiologists are core users of AngioDynamics’ vascular access and ablation tools because they perform image-guided procedures that match the Company’s product mix. In fiscal 2025, AngioDynamics generated about $300 million in net sales, and adoption by these physicians can lift device use across hospital procedure volumes and purchasing decisions.
Cardiologists and vascular surgeons
Cardiologists and vascular surgeons are core customers for AngioDynamics, because they treat peripheral vascular disease and venous conditions and depend on endovascular therapies and access tools every day. With peripheral artery disease affecting about 8.5 million U.S. adults, their buying decisions hinge on reliability, precise delivery, and smooth procedural performance.
Urologists and interventional oncologists
Urologists and interventional oncologists are core users of AngioDynamics, Inc.'s ablation and oncology systems for targeted care. They prioritize millimeter-level precision and safety near sensitive structures, which is why advanced treatment platforms matter in over 2 high-risk specialties and in procedures where 1 mistake can change outcomes.
Critical care nurses and vascular access teams
Critical care nurses and vascular access teams are key users for AngioDynamics, Inc. because they manage lines, ports, and catheter placement support in inpatient care. Their day-to-day workflow shapes what gets bought, since they influence product choice, line maintenance, and insertion success.
- Control bedside use
- Shape device selection
- Drive access demand
Hospitals, oncology centers, and dialysis facilities
Hospitals, oncology centers, and dialysis facilities are AngioDynamics, Inc.'s core buyers for vascular access, oncology, and kidney-care tools, so one purchasing decision can spread across many procedures. In FY2025, that mattered because these sites drive recurring use of consumables, not just one-off device sales, and they often set product standards across multiple care teams.
- High procedure volume supports repeat orders.
- Consumables create steady follow-on demand.
- Large sites help standardize adoption.
AngioDynamics Sales Depend on Key Hospital and Physician Buyers
AngioDynamics, Inc. sells mainly to hospitals, oncology centers, and dialysis facilities, with interventional radiologists, cardiologists, vascular surgeons, urologists, and interventional oncologists driving use. FY2025 net sales were about $300 million, so buying decisions from these care teams and sites matter across recurring procedures and consumable demand.
| Customer segment | Why it matters |
|---|---|
| Hospitals and centers | Set standards and buy volume |
| Physicians | Drive procedure use |
Cost Structure
Research and development expense
In fiscal 2025, AngioDynamics spent about $24 million on research and development, funding product design, testing, and platform upgrades. That spend is critical for new devices and longer-term medtech competitiveness, because innovation is what keeps the pipeline moving.
Manufacturing and materials cost
Building sterile medical devices is labor and material heavy, with added costs for testing, packaging, and inventory handling. In AngioDynamics' FY2025 model, quality control and clean-room production stay a major cost driver, and even small yield gains can move gross profit fast.
Sales and marketing expense
AngioDynamics, Inc. keeps sales and marketing high because direct reps, distributor support, and commercial programs need constant field coverage. In fiscal 2025, this spend also backed product launches and physician education, which fits a relationship-led medtech model where access and trust drive sales.
Regulatory and quality compliance cost
For AngioDynamics, Inc., regulatory and quality compliance cost is a fixed part of doing business: device makers must fund documentation, audits, post-market surveillance, and quality systems to keep approvals and sell in regulated markets. In fiscal 2025, AngioDynamics reported $0.0M?
- Mandatory for FDA and global market access
- Supports approvals, recalls control, and surveillance
- Raises overhead before revenue is earned
General and administrative expense
In FY2025, AngioDynamics, Inc. general and administrative expense reflects the fixed cost base behind Latham, New York headquarters, plus finance, IT, legal, and HR. Public-company reporting, audit, and SOX compliance add overhead, while logistics and customer service keep this line sticky even when sales move.
HQ, finance, IT, legal, HR.
Public-company reporting raises overhead.
Logistics and service add cost.
AngioDynamics’ FY2025 Cost Base: R&D, Quality, and Sticky Overhead
AngioDynamics, Inc. cost structure in fiscal 2025 was led by about $24 million in research and development, plus high labor, materials, quality-control, and sterile manufacturing costs. Sales and marketing, regulatory compliance, and general and administrative overhead stayed sticky because the Company Name runs a regulated, field-driven medtech model.
| FY2025 cost driver | Amount |
|---|---|
| R&D | $24 million |
| Quality and sterile production | Major cost base |
| Sales and marketing | High and recurring |
Revenue Streams
Vascular access device sales
In FY2025, AngioDynamics generated about $306 million in net sales, with vascular access devices such as catheters, PICCs, midlines, ports, and dialysis products feeding hospital and critical care demand. These items can repeat through replacement cycles and procedure volume, so sales can recur as line use stays high.
Oncology ablation system sales
AngioDynamics, Inc.'s oncology ablation revenue comes from NanoKnife and Solero systems, which sell advanced tech for oncology and soft tissue ablation; the stream includes capital equipment plus recurring consumables. In FY2025, the company reported about $285 million in net sales, and these platforms remained part of its Med Tech mix.
Endovascular therapy product sales
Endovascular therapy product sales drive AngioDynamics, Inc.’s vascular care revenue through thrombus management, atherectomy, and venous insufficiency tools used in interventional procedures. Demand rises with physician use and hospital adoption; these products are a core part of AngioDynamics, Inc.’s FY2025 vascular platform.
Disposable and single-use consumables
AngioDynamics’ disposable and single-use consumables drive recurring revenue through catheters, guidewires, introducer kits, and accessories; these items must be repurchased for each procedure. In FY2025, AngioDynamics reported net sales of about $288 million, and this stream stays core because procedure-based care creates steady replacement demand.
- Repeat purchases from every case
- Single-use items support recurring sales
- Procedure volumes drive demand
International distributor and direct sales
AngioDynamics, Inc. used both direct sales and distributor channels to reach U.S. and international customers in FY2025, helping broaden commercialization across its portfolio. The company reported net sales of $307.9 million in FY2025, so this mix matters for scale and market access.
- Direct sales support key accounts
- Distributors expand geographic reach
- FY2025 net sales: $307.9 million
AngioDynamics Revenue: Recurring, Case-Driven Growth
AngioDynamics, Inc.'s revenue streams are mainly case-driven and recurring: single-use vascular access consumables, oncology ablation systems with follow-on disposables, and endovascular tools sold through direct and distributor channels. In FY2025, net sales were about $307.9 million, with $306 million from vascular access and $285 million from oncology ablation mix noted in the business model.
| Stream | FY2025 |
|---|---|
| Net sales | $307.9M |
| Vascular access | $306M |
| Oncology ablation | $285M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.